News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EU Agency Calls for Restrictions on Sanofi (France) (SASY.PA)'s Multaq


9/23/2011 8:11:46 AM

Risks of liver, cardiovascular or lung issues stemming from Sanofi's Multaq irregular heart beat drug mean its use should be restricted, Europe's drug regulator said on Thursday following a safety review. The decision could raise further pressure on Sanofi to speed up the replenishment of a drug pipeline which has been drastically diminished after a top-to-bottom review. Following a monthly meeting, the regulator's Committee on Medicinal Products for Human Use (CHMP) in London recommended the drug should only be prescribed "after alternative treatment options have been considered".

Read at Reuters
Read at Bloomberg
Read at News Release
Read at Wall Street Journal
Read at RTT News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES